These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26854475)

  • 1. Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study.
    Mueller JL; King LY; Johnson KB; Gao T; Nephew LD; Kothari D; Simpson MA; Zheng H; Wei L; Corey KE; Misdraji J; Lee JH; Lin MV; Gogela NA; Fuchs BC; Tanabe KK; Gordon FD; Curry MP; Chung RT
    Clin Transplant; 2016 Apr; 30(4):452-60. PubMed ID: 26854475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables.
    Duarte-Rojo A; Veldt BJ; Goldstein DD; Tillman HL; Watt KD; Heimbach JK; McHutchison JG; Poterucha JJ; Vargas-Vorackova F; Charlton MR
    Transplantation; 2012 Jul; 94(2):197-203. PubMed ID: 22766768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
    Lange CM; Moradpour D; Doehring A; Lehr HA; Müllhaupt B; Bibert S; Bochud PY; Antonino AT; Pascual M; Farnik H; Shi Y; Bechstein WO; Moench C; Hansmann ML; Sarrazin C; Lötsch J; Zeuzem S; Hofmann WP
    J Hepatol; 2011 Aug; 55(2):322-7. PubMed ID: 21147186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C.
    Dunn W; O'Neil M; Zhao J; Wu CH; Roberts B; Chakraborty S; Sherman C; Weaver B; Taylor R; Olson J; Olyaee M; Gilroy R; Schmitt T; Wan YJ; Weinman SA
    Hepatology; 2014 Feb; 59(2):453-60. PubMed ID: 24123231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection.
    Charlton MR; Thompson A; Veldt BJ; Watt K; Tillmann H; Poterucha JJ; Heimbach JK; Goldstein D; McHutchison J
    Hepatology; 2011 Jan; 53(1):317-24. PubMed ID: 21254179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens.
    Tamaki N; Kurosaki M; Higuchi M; Takada H; Nakakuki N; Yasui Y; Suzuki S; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Ogawa S; Tanaka Y; Asahina Y; Izumi N
    PLoS One; 2015; 10(9):e0137351. PubMed ID: 26352693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host genetics predict clinical deterioration in HCV-related cirrhosis.
    King LY; Johnson KB; Zheng H; Wei L; Gudewicz T; Hoshida Y; Corey KE; Ajayi T; Ufere N; Baumert TF; Chan AT; Tanabe KK; Fuchs BC; Chung RT
    PLoS One; 2014; 9(12):e114747. PubMed ID: 25504078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus.
    Wong GL; Chan HL; Tse CH; Chan PO; Cheng JC; Cheng JS; Lau SH; Lee EK; Ma JM; Chan AW; Choi PC; Wong VW
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1040-8. PubMed ID: 25639146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication.
    Barbera F; Russelli G; Pipitone L; Pietrosi G; Corsale S; Vizzini G; Gridelli B; Conaldi PG
    New Microbiol; 2015 Apr; 38(2):201-10. PubMed ID: 25938745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation.
    Biggins SW; Trotter J; Gralla J; Burton JR; Bambha KM; Dodge J; Brocato M; Cheng L; McQueen M; Forman L; Chang M; Kam I; Everson G; Spritz RA; Klintmalm G; Rosen HR
    J Hepatol; 2013 May; 58(5):969-76. PubMed ID: 23333445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.
    Scheiner B; Mandorfer M; Schwabl P; Payer BA; Bucsics T; Bota S; Aichelburg MC; Grabmeier-Pfistershammer K; Stättermayer A; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T
    PLoS One; 2015; 10(11):e0143429. PubMed ID: 26599080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.
    Valenti L; Aghemo A; Stättermayer AF; Maggioni P; De Nicola S; Motta BM; Rumi MG; Dongiovanni P; Ferenci P; Colombo M; Fargion S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1434-42. PubMed ID: 22530607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age.
    Senkerikova R; Frankova S; Jirsa M; Kreidlova M; Merta D; Neroldova M; Chmelova K; Spicak J; Sperl J
    PLoS One; 2019; 14(9):e0222609. PubMed ID: 31527889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.
    Ampuero J; Del Campo JA; Rojas L; García-Lozano JR; Solá R; Andrade R; Pons JA; Navarro JM; Calleja JL; Buti M; González-Escribano MF; Forns X; Diago M; García-Samaniego J; Romero-Gómez M
    Ann Hepatol; 2014; 13(4):356-63. PubMed ID: 24927606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of IL28B polymorphism and graft survival in patients with hepatitis C undergoing liver transplantation.
    Allam SR; Krüger B; Mehrotra A; Schiano T; Schröppel B; Murphy B
    PLoS One; 2013; 8(1):e54854. PubMed ID: 23382988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: a meta-analysis.
    Zhang L; Lu Q; Yang Z; Wang X; Cai L; Liu X; Liao R; Yang X; Chen Y; Yang Z
    Hum Immunol; 2014 Dec; 75(12):1268-75. PubMed ID: 25225180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.
    Firpi RJ; Dong H; Clark VC; Soldevila-Pico C; Morelli G; Cabrera R; Norkina O; Shuster JJ; Nelson DR; Liu C
    Liver Int; 2013 Jan; 33(1):72-8. PubMed ID: 23107586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
    World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.